Sensus Healthcare Inc - רווח נקי למניה בארבעת הרבעונים האחרונים SRTS

Sensus Healthcare, Inc. (SRTS) is competing for market share against laser manufacturers and pharma behemoths by offering alternatives to traditional surgery. The business relies on its monopoly status in the non-invasive basal cell carcinoma destruction segment utilizing compact units. This chart of the asset's market value demonstrates an EPS TTM of -430.70, while demographic growth and stable demand fully shield the issuer's financial results from macroeconomic shocks.

The efficiency of Sensus Healthcare, Inc. (SRTS) robotic production lines for cancer therapy systems is directly reflected in the net profit available to shareholders. By analyzing the 12-month YoY earnings per share growth rate, which recorded a value of -430.70, an investor assesses the percentage change in EPS (TTM), allowing for the identification of the business's actual scaling speed and the avoidance of overvalued assets.